Neurocrine Biosciences Inc - Company Profile
Powered by 
All the data and insights you need on Neurocrine Biosciences Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Neurocrine Biosciences Inc Strategy Report
- Understand Neurocrine Biosciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Neurocrine Biosciences Inc (Neurocrine) discovers, develops, and sells pharmaceutical products for the treatment of neurologic, neuropsychiatric, and neuroendocrine-related diseases and disorders. Its lead product, Ingrezza (valbenazine) capsule, is a US FDA-approved selective vesicular monoamine transporter 2 inhibitor for the treatment of adults with tardive dyskinesia (TD). The company's major pipeline products include valbenazine in Phase III clinical trials for the treatment of chorea in Huntington’s disease and adjunctive treatment of Schizophrenia; NBI-1065846 in Phase II clinical trial for anhedonia in depression; NBI-827104 in Phase II clinical trials for rare pediatric epilepsy; NBI-921352 in Phase II trials for focal onset seizures in adults; crinecerfont (NBI-74788), a corticotropin-releasing factor1 (CRF1) antagonist in Phase III trials for congenital adrenal hyperplasia in adults and in Phase II trials for congenital adrenal hyperplasia in pediatric patients. Neurocrine is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
12780 El Camino Real, San Diego, California, 92130-2042
Website
www.neurocrine.com
Telephone
1 858 6177600
No of Employees
1,400
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NBIX (NASD)
Revenue (2022)
$1.5B
31.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
72.4%
(2022 vs 2021)
Market Cap*
$11.5B
Net Profit Margin (2022)
XYZ
31.4%
(2022 vs 2021)
* As of and is in US$
Neurocrine Biosciences Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Ongentys (Opicapone) Capsules | Ingrezza |
| Ingrezza (Valbenazine) Capsules | Ongentys |
| Orilissa Tablets | Orilissa |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In January, the company and Voyager Therapeutics entered into a partnership to advance multiple gene therapies to treat neurological diseases. |
| 2022 | Contracts/Agreements | In August, the company entered into an agreement to acquire Diurnal. |
| 2021 | Contracts/Agreements | In November, the company and Sosei Group Corp signed a strategic collaboration and licensing agreement to develop novel muscarinic receptor agonists for Schizophrenia and other neuropsychiatric disorders. |
Competitor Comparison
| Key Parameters | Neurocrine Biosciences Inc | Pfizer Inc | Eli Lilly and Co | Newron Pharmaceuticals SpA | Auspex Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Italy | United States of America |
| City | San Diego | New York | Indianapolis | Bresso | La Jolla |
| State/Province | California | New York | Indiana | - | California |
| No. of Employees | 1,400 | 83,000 | 39,000 | 23 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William H. Rastetter, Ph.D. | Chairman | Executive Board | 2011 | 73 |
| Kevin C. Gorman, Ph.D. | Director; Chief Executive Officer | Executive Board | 2008 | 65 |
| Matthew C. Abernethy | Chief Financial Officer | Senior Management | 2017 | 43 |
| Kyle W. Gano, Ph.D | Chief Business Development Officer; Chief Strategy Officer | Senior Management | 2020 | 50 |
| Darin M. Lippoldt | Chief Legal Officer; Secretary | Senior Management | 2014 | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward